USANA Health Sciences, Inc.

USANA Health Sciences, Inc. (USNA) Market Cap

USANA Health Sciences, Inc. has a market capitalization of $370.2M.

Financials based on reported quarter end 2026-01-03

Price: $20.06

β–² 1.00 (5.25%)

Market Cap: 370.25M

NYSE Β· time unavailable

CEO: Kevin G. Guest

Sector: Consumer Defensive

Industry: Packaged Foods

IPO Date: 1994-04-04

Website: https://www.usana.com

USANA Health Sciences, Inc. (USNA) - Company Information

Market Cap: 370.25M Β· Sector: Consumer Defensive

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Analyst Sentiment

50%
Hold

Based on 0 ratings

Analyst 1Y Forecast: $0.00

Average target (based on 3 sources)

Consensus Price Target

Low

$35

Median

$35

High

$35

Average

$35

Potential Upside: 74.5%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ USANA HEALTH SCIENCES INC (USNA) β€” Investment Overview

🧩 Business Model Overview

USANA sells dietary supplements and related health products through a direct-selling distribution model. The value chain centers on (1) product development and sourcing, (2) manufacturing and quality systems, (3) brand-driven education and promotion, and (4) distribution via independent representatives who recruit and build customer and personal-consulting relationships.

This model converts marketing and community building into repeat purchasing behavior: customers typically buy routinely, while representatives earn primarily from a combination of personal product sales and distributor-level volume, creating incentives to drive both retention and volume growth.

πŸ’° Revenue Streams & Monetisation Model

Revenue is largely driven by recurring consumption of supplements, supplemented by seasonal or product-cycle purchasing. Monetisation benefits from a sell-through pattern that is more habitual than one-off transactional retail categories.

Gross margin structure tends to be influenced by product mix (core health categories versus newer offerings), sourcing and manufacturing economics, and promotional intensity required to sustain representative productivity. Operating leverage is most attainable when representative productivity remains stable and promotional spend scales more slowly than revenue.

Because distribution is partner-led rather than heavily dependent on owned retail footprint, USANA’s incremental revenue can be supported with relatively modest incremental fixed costsβ€”though this depends on maintaining representative recruitment, training, and consumer demand.

🧠 Competitive Advantages & Market Positioning

Primary moat: Switching costs and relationship-based distribution. USANA’s model creates stickiness through ongoing replenishment needs, brand familiarity, and representative guidance. Customers often build routines around specific formulations and advice, reducing the willingness to switch to competing brands without disruption.

Secondary moat: Intangible assetsβ€”brand credibility in health and wellness. In supplements, trust and perceived quality are critical. USANA’s long-standing presence and emphasis on quality systems can support conversion and retention, particularly where consumers seek guidance and consistency rather than commodity pricing.

Distribution-scale advantage (network-like effect). While direct selling is not a pure marketplace network, it does exhibit network dynamics: an established base of representatives and community structures can improve lead generation, training throughput, and selling efficiency. New entrants face both time-to-scale and the need to fund recruitment and education.

Overall, the competitive challenge for a new or smaller competitor is not only product formulation, but achieving comparable representative penetration, brand trust, and ongoing consumer ordering patterns.

πŸš€ Multi-Year Growth Drivers

1) Category growth within wellness and preventive health. Structural demand for supplements tied to nutrition, longevity, and everyday wellness supports a larger β€œbasket” for repeat purchasing.

2) Geographic expansion and channel penetration. Growth opportunities often come from deeper penetration in existing markets and expansion into underpenetrated regions where direct selling ecosystems can be built and scaled over time.

3) Product line breadth and innovation pipeline. Multi-category coverage enables cross-selling to existing customers and helps maintain representative productivity when demand shifts by consumer preference.

4) Retention-driven compounding. In recurring-consumption models, improved retention and representative stability can compound over multiple years, supporting a durable revenue base even when new customer acquisition is less aggressive.

Over a 5–10 year horizon, the key driver is the ability to sustain representative capacity and consumer retention while expanding distribution and maintaining disciplined product-mix management.

⚠ Risk Factors to Monitor

Representative incentive sustainability and channel health: Direct selling depends on recruitment and training. If representative economics weaken (through demand softness, increased competition, or constrained purchasing), productivity can fall and revenue growth may require higher promotional intensity.

Regulatory and compliance pressure: Dietary supplements operate within evolving regulatory frameworks for claims, labeling, manufacturing quality, and marketing practices. Adverse regulatory outcomes could require operational changes or limit certain promotions.

Reputation and quality perception risk: Supplements are sensitive to quality incidents, contamination concerns, or adverse consumer sentiment. Quality events can quickly impair demand and increase compliance costs.

Competitive intensity and pricing dynamics: The category attracts both established and low-cost entrants. If competition forces increased discounts or marketing spend, margin durability becomes harder.

Working capital and supply chain volatility: Product lead times, raw material costs, and manufacturing throughput can affect costs and availability, with second-order effects on fulfillment and inventory management.

πŸ“Š Valuation & Market View

USANA is typically valued by the market through a blend of sales-based and cash-flow-based approaches, reflecting the steady-state nature of supplement consumption and the uncertainty around channel-led growth.

Key valuation drivers generally include:

  • Revenue durability (repeat purchase behavior and customer retention)
  • Gross margin stability driven by product mix and promotional discipline
  • Operating leverage tied to representative productivity and marketing efficiency
  • Growth quality (whether growth comes from retention/cross-sell versus increasingly aggressive incentives)

In this sector, changes in market perception often matter as much as absolute growth: when channel health and margins appear resilient, valuation tends to support a higher multiple of revenue and stronger cash-flow expectations; when channel sustainability or regulatory risk rises, investors typically demand a discount.

πŸ” Investment Takeaway

USANA’s long-term thesis rests on a relationship-driven direct-selling model that can create meaningful switching friction via routine consumption, representative guidance, and brand trust. The primary investment question is not whether supplements remain a category demand area, but whether USANA can maintain channel productivity and margin discipline while extending distribution and refreshing its product mix. If these elements hold, the business can translate recurring purchasing behavior into durable cash generation over a multi-year horizon.


⚠ AI-generated β€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-01-03

"USNA reported revenue of $226.2M for the latest quarter, with a net loss of $1.775M, translating to an EPS of -$0.097. The company's financial performance shows a decline, as indicated by a 1-year price change of -37.56%, reflecting weakened market performance. With negative free cash flow of -$5.159M and operating cash flow also in the red, cash generation remains a concern. The balance sheet shows total assets of $742.9M against total liabilities of $156.6M, resulting in a solid equity base of $586.3M and negative net debt of -$144.4M, implying strong liquidity. However, the revenue decline, negative profitability, and lack of dividends correlate to investor risk concerns, impacting shareholder returns significantly. The price target consensus stands at $35, indicating a potential upside from the current price of $17.01, although market sentiment remains weak reflecting the declining performance over the last year."

Revenue Growth

Neutral

Revenue is stable but growth is lacking.

Profitability

Neutral

Company is currently unprofitable with a net loss.

Cash Flow Quality

Neutral

Negative operating and free cash flows raise concerns.

Leverage & Balance Sheet

Neutral

Strong balance sheet with negative net debt but high total assets.

Shareholder Returns

Neutral

Significant price drop and no dividends reflect poor returns.

Analyst Sentiment & Valuation

Fair

Market is cautious despite a positive price target.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management framed FY26 as a confident reset toward omnichannel growth (midpoint net sales growth ~4%) driven by Rise and Hiya, with operational discipline (cost realignment: ~10% workforce impacted; ~$10M+ savings largely into SG&A). However, the Q&A highlighted why the guidance ranges remain wide: Rise upside depends on orders timing (some β€œin the back pocket” and possibly in the back half of the year), while Hiya is still early and ramping through Canada/UK (U.K. April) and Target (April). The biggest tangible financial headwind is not macroβ€”it’s structural: an effective tax rate of 55%–60% driven by geographic revenue/cost misalignment, with no precise bps improvement given. EPS execution is also exposed to mixβ€”Rise is guided to breakeven with thinner gross margin, which can pressure consolidated optics. Management’s tone is optimistic, but the analyst pressure surfaced real timing, mix, and tax-rate uncertainty.

AI IconGrowth Catalysts

  • Rise Wellness: launch and growth of Protein Pop, with additional flavors added for Target
  • Hiya: channel expansion and new market launches (Canada, U.K.), plus in-house manufacturing ramp
  • Omnichannel platform expansion to diversify revenue beyond the legacy China-centric model
  • Product innovation pipeline: refreshed branding and upgraded/new products launching globally in 2026
  • Operational shift to in-house manufacturing to increase speed/efficiency and reduce costs

Business Development

  • Retail commitments: 'in all the Target stores in the U.S.' (Target April launch referenced)
  • Costco: 'in all the Costco stores now as of last week' (Protein Pop rollout)
  • Target distribution: Protein Pop retail rollout; additional flavors going into Target
  • Hiya: distribution into Target (April), international expansion into Canada and the U.K.

AI IconFinancial Highlights

  • Fiscal 2026 net sales growth guidance midpoint ~4% (wide ranges discussed by analysts; management emphasis on multiple swing factors)
  • Effective income tax rate guidance for fiscal 2026: 55% to 60% (geographic misalignment between revenue and costs incurred highlighted as primary driver)
  • FY25 end inventory: $107M, up $35M (+48%); ~80% of YoY increase attributed to Rise/Hiya initiatives
  • Rise Wellness expected to operate at approximately breakeven in fiscal 2026 (thin gross margin referenced as a mix headwind for company-level optics)
  • Cost realignment in Q4: impacted ~10% of workforce; ~$10M+ net savings, primarily repurposed into SG&A (not expected to materially change gross margin/cost of sales)
  • 52-week fiscal 2026 includes one less week of operations vs fiscal 2025 (noted as a modeling consideration)

AI IconCapital Funding

  • No specific buyback/debt amounts disclosed in the provided transcript
  • Management references 'solid financial position' and 'strong cash balance' sufficient to invest thoughtfully (no quantified runway provided)

AI IconStrategy & Ops

  • Technology modernization: accelerate technology roadmap using third-party platforms; incremental investment not factored into FY26 outlook (scope/timing/capital requirements TBD)
  • Cost efficiency initiatives: workforce reduction (~10%) and net savings ~ $10M+; savings repurposed mainly to SG&A
  • Manufacturing transition: moving to in-house manufacturing for Hiya to begin manufacturing products (raw materials inventory built ahead of ramp)
  • Brand partner/field execution emphasis: reinvigorate global sales momentum via enhanced field support, market-specific strategies, and leadership engagement

AI IconMarket Outlook

  • Hiya launch timing: U.K. 'go live in April'; Target 'go live' referenced for April; Canada just launched (within 'next 3 weeks' for U.K.)
  • Seasonality model (core nutrition): China Lunar New Year drives stronger Q1 with Q2 momentum; Q3 lull due to summer/vacations; Q4 rebuild for next year
  • Management expects elevated inventory levels throughout FY26 due to retail/channel/geography expansion for Rise and Hiya

AI IconRisks & Headwinds

  • Tax rate pressure: geographic misalignment between where revenue is generated vs costs incurred; already evident in H2 FY25 and worsened by recognition of certain one-time costs
  • Guidance swing factors are driven by timing/commitment of retail orders and new market ramp (wide ranges for revenue/EPS guidance); depends on orders in the back half of the year for Rise
  • Mix headwind: as Rise grows, company-level gross margin optics may worsen because Rise is breakeven in FY26 and has a thinner gross margin
  • Seasonality: core nutrition promotional cadence around Lunar New Year creates non-linear quarter-to-quarter activity
  • Operational hurdle: technology spend requires incremental investment not yet included in FY26 guidance (timing/capital not finalized)

Sentiment: MIXED

Note: This summary was synthesized by AI from the USNA Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (USNA)

Β© 2026 Stock Market Info β€” USANA Health Sciences, Inc. (USNA) Financial Profile